Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
cGMP Non-Compliance Recap 2020
The coronavirus pandemic changed the way we lived our lives, and
regulatory agencies were no except
New Drugs Approvals by FDA and EMA: 2020 Recap
The year
2020 was an eventful year for the pharmaceutical industry, with several
companies across
Covid-19 HCQ update: Studies in France, Brazil, China raise more questions on its efficacy, safety
Last month, we had carried an article ‘Hydroxychloroquine: Hype versus reality’ that
hi
Chinese industrial activity revival at 98.6 percent, officials assure of API supplies
While the world feels the heat of the Covid-19 pandemic with the global pharmaceutical supply chain
Hydroxychloroquine: Hype versus reality
The
President of United States Donald Trump’s
tweet
late last week has swung the pharmaceut
Teva to market cannabis inhaler; FDA makes quality metrics voluntary
This week, Phispers brings you news on J&J’s plans to acquire Actelion and Teva’s ne
The silver lining in Ipca’s Import Alert blues
Ipca Laboratories finished dosage facilities at Silvasa and
Pithampur (India) were put on the FDA Im
With a $1.2 billion buy, Concordia re-affirms that old drugs are indeed gold!
Canada based, Concordia Healthcare continued their buying spree of old, established drug brands
